5X74
The crystal Structure PDE delta in complex with compound (R, R)-1g
Summary for 5X74
| Entry DOI | 10.2210/pdb5x74/pdb |
| Related | 5X72 5X73 |
| Descriptor | Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta, (2R)-2-(2-fluorophenyl)-3-[2-[4-[(2R)-2-(2-fluorophenyl)-4-oxidanylidene-1,2-dihydroquinazolin-3-yl]piperidin-1-yl]ethyl]-1,2-dihydroquinazolin-4-one (3 entities in total) |
| Functional Keywords | lipid binding protein |
| Biological source | Homo sapiens (Human) |
| Cellular location | Cytoplasm, cytosol : O43924 |
| Total number of polymer chains | 1 |
| Total formula weight | 17992.62 |
| Authors | |
| Primary citation | Jiang, Y.,Zhuang, C.,Chen, L.,Lu, J.,Dong, G.,Miao, Z.,Zhang, W.,Li, J.,Sheng, C. Structural Biology-Inspired Discovery of Novel KRAS-PDE delta Inhibitors J. Med. Chem., 60:9400-9406, 2017 Cited by PubMed Abstract: Structural biology is a powerful tool for investigating the stereospecific interactions between a protein and its ligand. Herein, an unprecedented chiral binding pattern was observed for inhibitors of KRAS-PDEδ interactions. Virtual screening and X-ray crystallography studies revealed that two enantiomers of a racemic inhibitor could bind at different sites. Fragment-based drug design was used to identify highly potent PDEδ inhibitors that can be used as promising lead compounds for target validation and antitumor drug development. PubMed: 28929751DOI: 10.1021/acs.jmedchem.7b01243 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.25 Å) |
Structure validation
Download full validation report






